[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digital-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digital-ulcer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535803","study-of-diosmin-for-the-treatment-of-digital-ulcers-in-systemic-sclerosis-100535803",false,"NCT06256575","Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis","Treatment of Digital Ulcers in Systemic Sclerosis With Diosmin: A Randomized, Double-blind, Placebo-controlled Multi-centre Pilot Study","Inclusion Criteria:\n\n* Diagnosis of systemic sclerosis (scleroderma)\n* At least one \"active\" digital ulcer\n* Medication for systemic sclerosis unchanged for 30 days\n\nExclusion Criteria:\n\n* Infection or gangrene in ulcer\n* Citrus allergy\n* Unstable heart, kidney, or liver disease\n* Active infection of any type\n* Current cancer treatment or uncured cancer\n* Pregnancy or breast feeding","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.",[26,27],"Scleroderma, Systemic","Digital Ulcer",[29,30,31,32],"SSc","Digital Ulcers","Sclerosis","Scleroderma","RECRUITING","2025-12-02",{"date":36,"type":37},"2025-12-04","ACTUAL",{"date":39,"type":37},"2025-05-02",{"date":41,"type":20},"2027-08-15",{"name":43,"class":44},"Primus Pharmaceuticals","INDUSTRY",5,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100302028","phase-1-mesenchymal-stromal-cells-as-treatment-for-digital-ulcers-in-systemic-sclerosis-100302028","NCT03211793","Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis","Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis: the MANUS Trial","MANUS","Inclusion Criteria:\n\n* Established diagnosis of SSc according to the 2013 ACR\u002FEULAR criteria\n* At least one active digital ulcer (painful area, \\>2 mm in diameter with visible depth and loss of dermis) refractory to intravenous prostacyclins\n\n  * 'Refractory to prostacyclins' is defined as\n  * Worsening of ulcer(s) within 1 month after prostacyclins iv\n  * No improvement of ulcer(s) after 2 months after prostacyclins iv, as judged by the referring physician\n  * Recurrence of exactly the same ulcer(s) (same location) within 3 months after prostacyclins iv\n* Written informed consent\n\nExclusion Criteria:\n\n* Ulcer with underlying calcinosis (ruled out by X-ray prior to screening\u002Finclusion)\n* History of neoplasm or malignancy in the past 10 years\n* Pregnancy or unwillingness to use adequate contraception during study\n* Serious known concomitant disease with life expectancy \\\u003C1 year\n* Uncontrolled hypertension\n* Uncontrolled acute or chronic infection with systemic symptoms (e.g. fever)\n* Follow-up impossible",{"count":55,"type":20},20,[57,58],"PHASE1","PHASE2","The MANUS Trial aims to examine the safety, feasibility and potential efficacy of intramuscularly injected allogeneic mesenchymal stromal cells as treatment for digital ulcers of systemic sclerosis.",[61,27],"Systemic Sclerosis",[63,64,65,66,67,68],"systemic sclerosis","scleroderma","digital ulcer","vasculopathy","mesenchymal stromal cell","mesenchymal stem cell","2025-09-03",{"date":71,"type":37},"2025-09-10",{"date":73,"type":37},"2021-10-06",{"date":75,"type":20},"2026-11-01",{"name":77,"class":78},"UMC Utrecht","OTHER",1]